Catheter-Related Bloodstream Infections (Crbsis) Market Growth Is Attributed To The Increasing Demand For Antibiotic Therapy

According to Precision Business Insights (PBI), the latest report, the Catheter-Related Bloodstream Infections (CRBSIs) market is expected to be worth USD 1.5 billion in 2022, growing at a significant CAGR from 2022 to 2028. The global Catheter-Related Bloodstream Infections (CRBSIs) market is segmented into the following types: By Type (Non-antibiotic, Antibiotic, Others), by route of administration (Oral and Intravenous), by Source of Infection/Causative Agents (Staphylococcus aureus, P. aeruginsa, Acinetobacter baumannii, E. Coli, K. Pneuminiae, Candida Sp., Others) and Geography (North America, Europe, Asia Pacific, Latin America, and MEA) Forecast to 2028. Key players' profiles in the Catheter-Related Bloodstream Infections (CRBSIs) market report are Merck Sharp & Dohme Corp, CorMedix, Inc., Geistlich Pharma, TauroPharm GmbH, Fresenius Medical Care, and Citius Pharmaceuticals. Central venous catheters (CVCs) are frequently needed for parenteral nourishment, blood transfusion, and cancer treatment in cancer patients. However, because of immunosuppression brought on by the disease and its treatments, cancer patients are particularly susceptible to infections, especially CVC-related infections (CRIs). The current IDSA recommendation for treating conditions brought on by catheters recommends continuing antibiotic treatment for at least 5 to 7 days following catheter removal. Other prescriptions or evaluations support similar requests. In cancer patients with CLABSI, coagulase-negative staphylococci (CoNS) are the most often found bacteria, followed by Gram-positive bacteria such as Staphylococcus aureus, Streptococci, and Enterococci. Increasing cancer patients drive the market worldwide.

View Detailed Report Description Here - https://precisionbusinessinsights.com/market-reports/catheter-related-bloodstream-infections-market/

Antibiotic Therapy Segment to Dominate the Catheter-Related Bloodstream Infections (CRBSIs) Market:
The antibiotic therapy segment is expected to account for a larger revenue share in the global Catheter-Related Bloodstream Infections (CRBSIs) market, with a value share worldwide. It is projected to grow at a 5.2% CAGR between 2022 and 2028. The antibiotic therapy was deemed appropriate if the isolate was sensitive to at least one antibiotic (such as vancomycin) and treatment began no later than 48 hours following catheter removal.

North America Catheter-Related Bloodstream Infections (CRBSIs) Market:
The North America market is expected to increase in the global Catheter-Related Bloodstream Infections (CRBSIs) market over the forecast period. It is projected to grow at a CAGR of 4.7% in the coming years. Current estimates state that more than 5 million CVCs are implanted annually in the USA. Increases the need for this infection's treatment in the area. Furthermore, the market for CRBSIs in the North American region is driven by the rising number of cancer patients' access to healthcare facilities.

Request sample report at https://precisionbusinessinsights.com/request-sample?product_id=56397

Strategic New Product Launches, Mergers, Acquisitions, and Agreements are the key strategies adopted by market players:
The global Catheter-Related Bloodstream Infections (CRBSIs) market further reveals that the key players are increasingly adopting strategies such as the launch of newer products, product launches, and long-term alliances to improve market revenue share and gain significant geographic presence across the region.

Detailed Segmentation:
Based on the type, the market is segmented into the following:
• Non-antibiotic
• Antibiotic
• Others

Based on the route of administration, the market is segmented into the following:
• Oral
• Intravenous

Based on the source of infection/causative agents, the market is segmented into the following:
• Staphylococcus aureus
• P. aeruginsa
• Acinetobacter baumannii
• E. Coli
• K. Pneuminiae
• Candida Sp.
• Others

Based on the distribution channel, the market is segmented into the following:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Request Methodology: https://precisionbusinessinsights.com/request-methodology?product_id=56397

Contact:
Mr. Satya
Precision Business InsightsTM | Toll Free: +1 866 598 1553
Email: sales@precisionbusinessinsights.com
Kemp House, 152 - 160 City Road, London EC1V 2NX
Web: https://precisionbusinessinsights.com/ | D U N S® Number: 852781747

About Precision Business Insights:
We are a market research company that strives to provide the highest quality market research insights. Our diverse market research experts are enthusiastic about market research and therefore produce high-quality research reports. We have over 500 clients with whom we have a good business partnership and capacity to provide in-depth research analysis for more than 30 countries. In addition to deliver more than 150 custom solutions, we already have accounts with the top five medical device manufacturers.

Precision Business Insights offers a variety of cost-effective and customized research services to meet research requirements. We are a leading research service provider because of our extensive database built by our experts and the services we provide.

This release was published on openPR.